Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT06289517
Recruiting Not applicable

PET Imaging of 68Ga-Her2-affibody in Tumors with High Her2 Expression

NCT06289517 · tracked via the Priya Life Science China tracker
Sponsor
Peking University First Hospital
Phase
Not applicable
Started
2024-05-28
Last updated
2024-12-18

Condition(s) studied

Neoplasms

Investigational drug(s) / intervention(s)

68Ga-Her2-affibody

68Ga-Her2-affibody: 68Ga-Her2-affibody is injected intravenously with a dose of 0.06-0.08 mCi/kg.

Study summary

This project uses HER2 protein as the target group of radiodrugs to explore the diagnostic efficacy, safety and metabolic characteristics of 68Ga-Her2-affibody in the expression status of HER2, aiming to provide a new imaging method for the determination of HER2 status in breast cancer At the same time, it also provides new methods and means for early diagnosis, accurate staging, recurrence judgment, treatment decision-making and prognosis judgment of malignant tumors such as lung cancer, gastrointestinal cancer and bladder cancer, and provides scientific basis for precise treatment of malignant tumors.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: \- patients with confirmed or suspected cancer; Signed written informed consent Exclusion Criteria: \-

Primary outcome measure(s)

  • The diagnostic efficacy of 68Ga-Her2-affibody PET/CT in the evaluation of breast cancer — 1 year
    the standardized Uptake Value (SUV) of lesions on 68Ga-Her2-affibody PET/CT

Trial sites (1)

FacilityCityRegionStatus
Peking University First Hospital Beijing Beijing Municipality Recruiting

More Peking University First Hospital trials in China

Dexmedetomidine-esketamine Combination and Chronic Postsurgical Pain After Spinal Surgery Starting soon
Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 ) Starting soon
Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease Recruiting
Intranasal Dexmedetomidine-esketamine Combination and Postoperative Cognitive Recovery in Older Patients Starting soon
Targeted Temperature Management on Delayed Neurocognitive Recovery in Older Patients After Major Cancer Surgery Starting soon

Other trials for the same condition

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer Active, not recruiting
China Metastatic Liver Cancer Clinical Registry Cohort Database Recruiting
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor Active, not recruiting
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma Recruiting
Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06289517 on ClinicalTrials.gov ↗ ← All trials in China